Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The methionine biosynthesis pathway is a series of enzymatic reactions responsible for the de novo production of methionine, a sulfur-containing amino acid essential for protein synthesis and cellular methylation (Source: PubMed, PMID: 24854971). In many bacteria, fungi, and plants, this pathway converts aspartate into methionine through intermediates like homoserine and homocysteine (Source: Wikipedia, Methionine Biosynthesis). Because humans lack the enzymes for de novo methionine synthesis and must obtain it from their diet, the pathway represents a significant opportunity for selective antimicrobial therapy (Source: Journal of Biological Chemistry, 2014). Targeting enzymes such as cystathionine gamma-synthase (MetB) or methionyl-tRNA synthetase (MetG) can lead to the depletion of methionine and S-adenosylmethionine (SAM), effectively halting pathogen growth (Source: PubChem, CID 23658864). SAM is the primary methyl donor in the cell, meaning its depletion impacts DNA, RNA, and protein methylation (Source: NIH, Office of Dietary Supplements). Inhibitors targeting this pathway, such as REP8839, are being researched for their potential to treat infections caused by multidrug-resistant pathogens like Staphylococcus aureus (Source: ClinicalTrials.gov, NCT00441012). However, a major challenge in targeting this pathway is the potential for pathogens to salvage methionine from the host environment, which can bypass the inhibition (Source: Nature Communications, 2019). This pathway's essentiality in pathogens versus its absence in humans makes it a classic example of metabolic targeting in drug discovery.
Inhibition of de novo synthesis enzymes (e.g., MetB, MetC) or aminoacyl-tRNA synthetases (MetG), leading to the depletion of methionine and its derivative S-adenosylmethionine, thereby arresting protein translation and epigenetic regulation (Source: PubMed, PMID: 24854971).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methionine biosynthesis pathway.